ClinicalTrials.gg
CompletedNCT00566020Updated Apr 4, 2017Results posted

A Clinical Evaluation Of BW430C (Lamotrigine) In Bipolar I Disorder- Long-term Extension Of Study SCA104779 (NCT00550407) -

A Phase 3 interventional study of BW430C (lamotrigine) in Bipolar Disorder, sponsored by GlaxoSmithKline. Completed at 52 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-04-04.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
92
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing lamotrigine in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Lamotrigine · Bipolar Disorder.

Enrollment
15th of 33
92 · median 72
Started
2008
with 3 others
Phase 3
11 of 33
none open now
Registered
20th of 33
by date
Lead sponsor
9 of 33
GlaxoSmithKline

Among the 33 studies testing lamotrigine in Bipolar Disorder, this one is the 15th largest by enrollment, is one of 4 that started in 2008, is one of 11 in phase 3, and was the 20th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

None of the 33 studies testing lamotrigine in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →

About lamotrigine

Lamotrigine: first FDA approval 1994 (LAMICTAL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies testing lamotrigine in Bipolar Disorder as a file.
02

Study summary

This study is planned to assess the long-term safety of lamotrigine in Japanese patients with bipolar I disorder who will continue into the 52-week extension upon completion of a double-blind comparative study (Study No.: SCA104779 (NCT00550407)), i.e. the patients who receive the addition of any additional treatment to intervene in a mood episode in the double-blind phase or the patients completing the double-blind phase.

03

Conditions studied

  • Bipolar Disorder

Browse trials for

Keywords

  • Open-label extension
  • Tolerability
  • Lamotrigine
  • Safety
  • Bipolar I disorder
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Of subjects participating in the preceding double-blind study, those who are judged by the investigator/sub-investigator to have well tolerated the double-blind treatment and to be eligible for the 52-week extension treatment
  • Sex: either sex. Female of will be eligible for inclusion in this study. However they have to have a negative pregnancy test at the start of this study, agree to further pregnancy testing at the time points determined in study assessments and procedures and practice one of the following methods of from the start of this study until the end of the follow-up examination:

Abstinence

Oral contraceptive, either combined or progestogen alone (except during the Dosage Adjustment Phase)

Injectable progestogen

Implants of levonorgestrel

Estrogenic vaginal ring (except during the Dosage Adjustment Phase)

Percutaneous contraceptive patches (except during the Dosage Adjustment Phase)

Intrauterine device (IUD) or intrauterine system (IUS) that meets the SOP effectiveness criteria as stated in the product label

Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject

Double barrier method: condom or occlusive cap (diaphragm or cervical / vault caps) plus spermicidal agent (foam / gel / film / cream / suppository)

  • In/Out patient: Either
  • : the subject capable of giving written informed consent

Exclusion criteria

Exclusion Criteria:

  • Has a score of 3 or more on item of the HAM-D related to suicide or is at a high suicidal risk in the judgment of the investigator/sub-investigator
  • Has a history of severe rash or rash due to anti-epileptic drugs
  • Patients with severe hepatic/renal/cardiac/pulmonary disorder or hematopoietic disorder. The severity refers to Grade 3 according to "the Classification of the Severity of Adverse Experiences" (PAB/SD Notification No. 80, dated 29 June 1992)
  • Patients have less than 5 years of remission history from (other than e.g. basal cell or squamous cell skin cancer, in-situ carcinoma of cervix or prostate CA in situ)
  • Patients with chronic hepatitis typeB and /or typeC which is positive of surface antigen (HBsAg)and/or antibody
  • Has an acute or chronic illness likely to impair drug absorption, distribution, metabolism or excretion or has any unstable physical symptoms likely to require hospitalisation during participation in the study
  • Female patients who are pregnant or lactating, who may be pregnant, or who plan for pregnancy during the study
  • Has a history or current diagnosis of epilepsy
  • Has received an drug within 30 days of screening
  • Patients with a history of drug allergy to any ingredient of the test-drug
  • Patients whom the investigator or sub-investigator considers ineligible for the study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    Lamotrigine

    study drug

    Drug: BW430C (lamotrigine)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Serious Adverse Event (SAE) and Any Non Serious Adverse Event

    An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of medicinal product, which does not necessarily have a causal relationship with the treatment. An SAE is any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or causes its prolongation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. A complete list of all SAEs and AEs experienced in the study can be found in the SAE/AE section.

    Time frame: From baseline (Week 0) until 2 weeks after the end of treatment (Week 54)

  2. Number of Participants With the Indicated Clinical Laboratory Test Values for Alkaline Phosphatase (ALP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), and Lactate Dehydrogenase (LDH)

    Participants in the study were evaluated for the following clinical laboratory parameters at the indicated time points: ALP, ALT, AST, GGT, and LDH. Participants were categorized as "High" for laboratory values above normal (reference) and as "Low" for laboratory values below normal ranges used by the central laboratory. Normal ranges: ALP, 104-338 International Units per liter (IU/L); ALT, 5-45 IU/L; AST, 10-40 IU/L; GGT, Male: 0-79 IU/L, Female: 0-48 IU/L; LDH 120-245 IU/L.

    Time frame: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/Early Withdrawal (EW)

  3. Number of Participants With Clinical Laboratory Test Values Out of the Normal Range and in the Normal Range for Total Bilirubin and Creatinine at Weeks 0, 6, 16, 28, 40, and 52/EW

    Participants in the study were evaluated for the following clinical laboratory parameters at the indicated time points: total bilirubin and creatinine. Participants were categorized as "High" for laboratory values above normal (reference) and as "Low" for laboratory values below normal ranges used by the central laboratory. Normal ranges: total bilirubin, 3.42-17.1 micromoles per liter (UMOL/L); creatinine, Male: 57.46-96.356 UMOL/L, Female: 40.664-72.488 UMOL/L.

    Time frame: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW

  4. Number of Participants With Clinical Laboratory Test Values Out of the Normal Range and in the Normal Range for Calcium, Cholesterol, Chloride, Potassium, Sodium, Triglycerides, and Urea/Blood Urea Nitrogen (BUN) at Weeks 0, 6, 16, 28, 40, and 52/EW

    Participants were evaluated for the following clinical laboratory parameters for blood chemistry at the indicated time points: electrolytes (calcium, chloride, potassium, sodium), cholesterol, triglycerides, and urea/BUN. Participants were categorized as "High" for laboratory values above normal (reference) and as "Low" for laboratory values below normal ranges used by the central laboratory. Normal ranges (micromoles per liter \[MMOL/L\]): calcium, 2.0459-2.495; chloride, 98-108; potassium, 3.5-5; sodium, 135-145; cholesterol, 3.879-5.66334; triglycerides, 0.565-1.6837; urea/BUN, 2.856-7.14.

    Time frame: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW

  5. Number of Participants With Clinical Laboratory Test Values Out of the Normal Range and in the Normal Range for Platelet Count and White Blood Cell Count at Weeks 0, 6, 16, 28, 40, and 52/EW

    Participants in the study were evaluated for the following clinical laboratory parameters of hematology at the indicated time points: platelet count and white blood cell count. Participants were categorized as "High" for laboratory values above normal (reference) and as "Low" for laboratory values below normal ranges used by the central laboratory. Normal ranges: platelet count, 140-379 GI (gibi; 10\^9) per liter (GI/L); white blood cell count, 3.5-9.7 GI/L.

    Time frame: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW

  6. Number of Participants With Clinical Laboratory Test Values Out of the Normal Range and in the Normal Range for Total Protein, Hemoglobin, and Hematocrit at Weeks 0, 6, 16, 28, 40, and 52/EW

    Participants in the study were evaluated for total protein, hemoglobin, and hematocrit at the indicated time points. Participants were categorized as "High" for laboratory values above normal (reference) and as "Low" for laboratory values below normal ranges used by the central laboratory. Normal ranges: total protein, 65-82 grams per liter (G/L); hemoglobin, Male: 136-183 G/L, Female: 112-152 G/L; hematocrit (proportion of 1), Male: 0.404-0.519, Female: 0.343-0.452.

    Time frame: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW

  7. Number of Participants With Clinical Laboratory Test Values Out of the Normal Range and in the Normal Range for Red Blood Cell Count at Weeks 0, 6, 16, 28, 40, and 52/EW

    Red blood cell count was measured in participants at the indicated time points. Participants were categorized as "High" for laboratory values above normal (reference) and as "Low" for laboratory values below normal ranges used by the central laboratory. Normal ranges: red blood cell count, Male: 4.38-5.77 TI (tebi; 10\^12)/L, Female: 3.76-5.16 TI/L.

    Time frame: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW

  8. Number of Participants in the Indicated Category for Urine Glucose, Urine Protein, and Urine Urobilinogen at Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW

    Urine glucose, urine protein, and urine urobilinogen were measured in participants at the indicated time points. In this dipstick (qualitative) test, the level of glucose, protein, and urobilinogen in urine samples was recorded as negative (NEG \[-\]), trace (TRA \[+/-\]), 1+, 2+, 3+, 4+, and 5+ (the plus sign increases with a higher level of glucose, protein, or urobilinogen in the urine: 1+=slightly positive, 2+=positive, 3+=high positive, 4+=very high positive, 5+=more positive than 4+).

    Time frame: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW

  9. Mean Systolic Blood Pressure and Diastolic Blood Pressure of Participants at Baseline (Week 0) and Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW

    Systolic and diastolic blood pressure was measured in participants at the indicated time points.

    Time frame: Baseline (Week 0) and Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW

  10. Mean Heart Rate of Participants at Week 0 (Baseline) and Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW

    Heart rate was measured in participants at the indicated time points.

    Time frame: Baseline (Week 0) and Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW

  11. Mean Weight of Participants at Baseline (Week 0) and Weeks 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW

    The weight of participants was recorded at the indicated time points.

    Time frame: Baseline (Week 0) and Weeks 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW

  12. Mean Body Mass Index (BMI) of All Participants at Week 0 (Baseline) and Weeks 6, 8, 12, 16, 20, 24, 28, 32,36, 40, 44, 48, and 52/EW

    The BMI for participants was calculated at the indicated time points as body weight in kilograms divided by height in meters squared.

    Time frame: Baseline (Week 0) and Weeks 0, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW

  13. Number of Participants With the Indicated Electrocardiogram (ECG) Findings at Weeks 0, 6, 28, and 52/EW

    ECGs were recorded in participants at the indicated time points. ECG findings, as determined by the physicians, were reported as normal, abnormal but not clinically significant (NCS), abnormal but clinically significant (CS), and no result. Specific definitions of ECG categorizations were not provided; physicians were expected to apply reasonable standards of clinical judgment.

    Time frame: Weeks 0, 6, 28, and 52/EW

Secondary outcomes

  1. Clinical Global Impressions of Severity (CGI-S) Total Score at Weeks 0, 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW

    The CGI-S is a standardized assessment tool that uses a 7-point scale to assess a participant's severity of illness. The total score ranges from 0 to 7: 0=not assessed, 1=normal, 2=borderline ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severly ill, 7=extremely ill. Higher scores reflect a higher severity of current illness states. The number of participants with an assessment varied depending on the number of assessments completed at each visit (indicated time points).

    Time frame: Weeks 0, 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW

  2. Change From Baseline in the Clinical Global Impressions of Severity (CGI-S) Total Score at Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW

    The CGI-S is a standardized assessment tool that uses a 7-point scale to assess a participant's severity of illness. The total score ranges from 0 to 7: 0=not assessed, 1=normal, 2=borderline ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severly ill, 7=extremely ill. Higher scores reflect a higher severity of current illness states. Change from baseline was calculated as the values at Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 (or EW) minus the baseline value (Week 0).

    Time frame: Baseline (Week 0) and Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW

  3. Hamilton Rating Scale for Depression (HAM-D) Scale Total Score at Weeks 6, 16, 28, 40, and 52/EW

    The HAMD-17 is a 17-item questionnaire that detects change and measures illness severity. Individual items were rated on a scale of 0-4 and 0-2, with the total HAMD-17 score ranging from 0 (not ill) to 52 (severely ill).

    Time frame: Weeks 6, 16, 28, 40, and 52/EW

  4. Change From Baseline in the Hamilton Rating Scale for Depression (HAM-D) Scale Total Score at Weeks 6, 16, 28, 40, and 52/EW

    The HAMD-17 is a 17-item questionnaire that detects change and measures illness severity. Individual items were rated on a scale of 0-4 and 0-2, with the total HAMD-17 score ranging from 0 (not ill) to 52 (severely ill). Change from baseline was calculated as the values at Week 6, 16, 28, 40, and 52 (or EW) minus the baseline value (Week 0).

    Time frame: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW

  5. Young Mania Rating Scale (YMRS) Total Score at Weeks 6, 16, 28, 40, and 52/EW

    The YMRS is an 11-item, multiple-choice diagnostic questionnaire used to measure the severity of disease in participants. Individual items (1=elevated mood, 2=increased motor activity, 3=sexual interest, 4=sleep, 5=irritability, 6=speech, 7=language thought disorder, 8=content, 9=disruptive aggressive behaviour, 10=appearance, 11=insight) were rated on a scale of 0-4 and 0-8. For all items, 0 is the "best" rating and 4 or 8 is the "worst" rating. YMRS total score was computed as the sum of the scores for the 11 items on the scale. The possible total scores range from 0 (best) to 60 (worst).

    Time frame: Weeks 6, 16, 28, 40, and 52/EW

  6. Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Weeks 6, 16, 28, 40, and 52/EW

    The YMRS is an 11-item, multiple-choice diagnostic questionnaire used to measure the severity of disease in participants. Individual items (1=elevated mood, 2=increased motor activity, 3=sexual interest, 4=sleep, 5=irritability, 6=speech, 7=language thought disorder, 8=content, 9=disruptive aggressive behaviour, 10=appearance, 11=insight) were rated on a scale of 0-4 and 0-8. YMRS total score (range of 0-60) was computed as sum of the scores for the 11 items on the scale. Change from baseline was calculated as the values at Week 6, 16, 28, 40, and 52 (or EW) minus the baseline value (Week 0).

    Time frame: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW

  7. Median Serum Lamotrigine 200 mg Concentration Among Participants With Concomitant Use of Inducer and Without Inhibitor (at the Timing of Blood Sample Collection)

    Pharmacokinetic (PK) samples were collected at Weeks 6, 16, 28, 40, 52/EW, and the plasma lamotrigine concentrations were measured. Participants were required to visit the study site without taking the investigational product on the morning of the PK blood sampling. Inhibitors are defined as drugs that inhibit lamotrigine glucuronidation (i.e., valproate). Inducers are defined as drugs that induce lamotrigine glucuronidation (e.g., carbamazepine). The median value presented is the median of all samples collected at Weeks 6, 16, 28, 40, and 52/EW.

    Time frame: from Week 6 to Week 52/EW

  8. Median Serum Lamotrigine 100 mg and 200 mg Concentration Among Participants With Concomitant Use of Inhibitor (at the Timing of Blood Sample Collection)

    PK samples were collected at Weeks 6, 16, 28, 40, 52/EW, and the plasma lamotrigine concentrations were measured. Participants were required to visit the study site without taking the investigational product on the morning of the PK blood sampling. Inhibitors are defined as drugs that inhibit lamotrigine glucuronidation (i.e., valproate). The median value presented is the median of all samples collected at Weeks 6, 16, 28, 40, and 52/EW.

    Time frame: from Week 6 to Week 52/EW

  9. Median Serum Lamotrigine 25, 100, 125, 150, 200, 225, 300, and 400 mg Concentrations Among Participants Without Concomitant Use of Inhibitor and Inducer

    PK samples were collected at Weeks 6, 16, 28, 40, 52/EW, and the plasma lamotrigine concentrations were measured. Participants were required to visit the study site without taking the investigational product on the morning of the PK blood sampling. Inhibitors are defined as drugs that inhibit lamotrigine glucuronidation (i.e., valproate). Inducers are defined as drugs that induce lamotrigine glucuronidation (e.g., carbamazepine). The median value presented is the median of all samples collected at Weeks 6, 16, 28, 40, and 52/EW.

    Time frame: from Week 6 to Week 52/EW

07

Results

Posted Jul 27, 2011

Participant flow

6-week Dosage Adjustment Phase
Participant flow — 6-week Dosage Adjustment Phase
MilestoneLamotrigine - Dosage Adjustment PhaseLamotrigine - Long-term Administration Phase
Started920
Completed850
Not completed70
Withdrew: Adverse event50
Withdrew: Lack of efficacy20
46-week Long-term Administration Phase
Participant flow — 46-week Long-term Administration Phase
MilestoneLamotrigine - Dosage Adjustment PhaseLamotrigine - Long-term Administration Phase
Started085
Completed068
Not completed017
Withdrew: Adverse event07
Withdrew: Physician decision07
Withdrew: Lost to follow-up02
Withdrew: Protocol-defined stopping criteria01

Outcome measures

PrimaryNumber of Participants With Any Serious Adverse Event (SAE) and Any Non Serious Adverse Event

An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of medicinal product, which does not necessarily have a causal relationship with the treatment. An SAE is any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or causes its prolongation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. A complete list of all SAEs and AEs experienced in the study can be found in the SAE/AE section.

Time frame:
From baseline (Week 0) until 2 weeks after the end of treatment (Week 54)
Reported as:
Number · participants
Number of Participants With Any Serious Adverse Event (SAE) and Any Non Serious Adverse Event
participantsLamotrigine
Participants with any SAE13
Participants with any non-serious AE75
PrimaryNumber of Participants With the Indicated Clinical Laboratory Test Values for Alkaline Phosphatase (ALP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), and Lactate Dehydrogenase (LDH)

Participants in the study were evaluated for the following clinical laboratory parameters at the indicated time points: ALP, ALT, AST, GGT, and LDH. Participants were categorized as "High" for laboratory values above normal (reference) and as "Low" for laboratory values below normal ranges used by the central laboratory. Normal ranges: ALP, 104-338 International Units per liter (IU/L); ALT, 5-45 IU/L; AST, 10-40 IU/L; GGT, Male: 0-79 IU/L, Female: 0-48 IU/L; LDH 120-245 IU/L.

Time frame:
Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/Early Withdrawal (EW)
Reported as:
Number · participants
Number of Participants With the Indicated Clinical Laboratory Test Values for Alkaline Phosphatase (ALP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), and Lactate Dehydrogenase (LDH)
participantsLamotrigine
ALP, High, Week 0; n=921
ALP, Normal, Week 0; n=9289
ALP, Low, Week 0; n=922
ALP, High, Week 6; n=842
ALP, Normal, Week 6; n=8482
ALP, Low, Week 6; n=840
ALP, High, Week 16; n=783
ALP, Normal, Week 16; n=7874
ALP, Low, Week 16; n=781
ALP, High, Week 28; n=771
ALP, Normal, Week 28; n=7776
ALP, Low, Week 28; n=770
ALP, High, Week 40; n=703
ALP, Normal, Week 40; n=7066
ALP, Low, Week 40; n=701
ALP, High, Week 52/EW; n=864
ALP, Normal, Week 52/EW; n=8681
ALP, Low, Week 52/EW; n=861
ALT, High, Week 0; n=926
ALT, Normal, Week 0; n=9286
ALT, Low, Week 0; n=920
ALT, High, Week 6; n=842
ALT, Normal, Week 6; n=8482
ALT, Low, Week 6; n=840
ALT, High, Week 16; n=783
ALT, Normal, Week 16; n=7875
ALT, Low, Week 16; n=780
ALT, High, Week 28; n=774
ALT, Normal, Week 28; n=7773
ALT, Low, Week 28; n=770
ALT, High, Week 40; n=703
ALT, Normal, Week 40; n=7067
ALT, Low, Week 40; n=700
ALT, High, Week 52/EW; n=863
ALT, Normal, Week 52/EW; n=8683
ALT, Low, Week 52/EW; n=860
AST, High, Week 0; n=923
AST, Normal, Week 0; n=9289
AST, Low, Week 0; n=920
AST, High, Week 6; n=842
AST, Normal, Week 6; n=8482
AST, Low, Week 6; n=840
AST, High, Week 16; n=782
AST, Normal, Week 16; n=7876
AST, Low, Week 16; n=780
AST, High, Week 28; n=772
AST, Normal, Week 28; n=7775
AST, Low, Week 28; n=770
AST, High, Week 40; n=703
AST, Normal, Week 40; n=7067
AST, Low, Week 40; n=700
AST, High, Week 52/EW; n=863
AST, Normal, Week 52/EW; n=8683
AST, Low, Week 52/EW; n=860
GGT, High, Week 0; n=925
GGT, Normal, Week 0; n=9287
GGT, Low, Week 0; n=920
GGT, High, Week 6; n=843
GGT, Normal, Week 6; n=8481
GGT, Low, Week 6; n=840
GGT, High, Week 16; n=784
GGT, Normal, Week 16; n=7874
GGT, Low, Week 16; n=780
GGT, High, Week 28; n=775
GGT, Normal, Week 28; n=7772
GGT, Low, Week 28; n=770
GGT, High, Week 40; n=704
GGT, Normal, Week 40; n=7066
GGT, Low, Week 40; n=700
GGT, High, Week 52/EW; n=865
GGT, Normal, Week 52/EW; n=8681
GGT, Low, Week 52/EW; n=860
LDH, High, Week 0; n=924
LDH, Normal, Week 0; n=9284
LDH, Low, Week 0; n=924
LDH, High, Week 6; n=844
LDH, Normal, Week 6; n=8477
LDH, Low, Week 6; n=843
LDH, High, Week 16; n=782
LDH, Normal, Week 16; n=7873
LDH, Low, Week 16; n=783
LDH, High, Week 28; n=773
LDH, Normal, Week 28; n=7772
LDH, Low, Week 28; n=772
LDH, High, Week 40; n=703
LDH, Normal, Week 40; n=7064
LDH, Low, Week 40; n=703
LDH, High, Week 52/EW; n=863
LDH, Normal, Week 52/EW; n=8682
LDH, Low, Week 52/EW; n=861
PrimaryNumber of Participants With Clinical Laboratory Test Values Out of the Normal Range and in the Normal Range for Total Bilirubin and Creatinine at Weeks 0, 6, 16, 28, 40, and 52/EW

Participants in the study were evaluated for the following clinical laboratory parameters at the indicated time points: total bilirubin and creatinine. Participants were categorized as "High" for laboratory values above normal (reference) and as "Low" for laboratory values below normal ranges used by the central laboratory. Normal ranges: total bilirubin, 3.42-17.1 micromoles per liter (UMOL/L); creatinine, Male: 57.46-96.356 UMOL/L, Female: 40.664-72.488 UMOL/L.

Time frame:
Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
Reported as:
Number · participants
Number of Participants With Clinical Laboratory Test Values Out of the Normal Range and in the Normal Range for Total Bilirubin and Creatinine at Weeks 0, 6, 16, 28, 40, and 52/EW
participantsLamotrigine
Total bilirubin, High, Week 0; n=925
Total bilirubin, Normal, Week 0; n=9287
Total bilirubin, Low, Week 0; n=920
Total bilirubin, High, Week 6; n=845
Total bilirubin, Normal, Week 6; n=8479
Total bilirubin, Low, Week 6; n=840
Total bilirubin, High, Week 16; n=782
Total bilirubin, Normal, Week 16; n=7876
Total bilirubin, Low, Week 16; n=780
Total bilirubin, High, Week 28; n=773
Total bilirubin, Normal, Week 28; n=7774
Total bilirubin, Low, Week 28; n=770
Total bilirubin, High, Week 40; n=704
Total bilirubin, Normal, Week 40; n=7066
Total bilirubin, Low, Week 40; n=700
Total bilirubin, High, Week 52/EW; n=868
Total bilirubin, Normal, Week 52/EW; n=8678
Total bilirubin, Low, Week 52/EW; n=860
Creatinine, High, Week 0; n=922
Creatinine, Normal, Week 0; n=9286
Creatinine, Low, Week 0; n=924
Creatinine, High, Week 6; n=842
Creatinine, Normal, Week 6; n=8481
Creatinine, Low, Week 6; n=841
Creatinine, High, Week 16; n=784
Creatinine, Normal, Week 16; n=7872
Creatinine, Low, Week 16; n=782
Creatinine, High, Week 28; n=772
Creatinine, Normal, Week 28; n=7773
Creatinine, Low, Week 28; n=772
Creatinine, High, Week 40; n=702
Creatinine, Normal, Week 40; n=7066
Creatinine, Low, Week 40; n=702
Creatinine, High, Week 52/EW; n=863
Creatinine, Normal, Week 52/EW; n=8679
Creatinine, Low, Week 52/EW; n=864
PrimaryNumber of Participants With Clinical Laboratory Test Values Out of the Normal Range and in the Normal Range for Calcium, Cholesterol, Chloride, Potassium, Sodium, Triglycerides, and Urea/Blood Urea Nitrogen (BUN) at Weeks 0, 6, 16, 28, 40, and 52/EW

Participants were evaluated for the following clinical laboratory parameters for blood chemistry at the indicated time points: electrolytes (calcium, chloride, potassium, sodium), cholesterol, triglycerides, and urea/BUN. Participants were categorized as "High" for laboratory values above normal (reference) and as "Low" for laboratory values below normal ranges used by the central laboratory. Normal ranges (micromoles per liter \[MMOL/L\]): calcium, 2.0459-2.495; chloride, 98-108; potassium, 3.5-5; sodium, 135-145; cholesterol, 3.879-5.66334; triglycerides, 0.565-1.6837; urea/BUN, 2.856-7.14.

Time frame:
Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
Reported as:
Number · participants
Number of Participants With Clinical Laboratory Test Values Out of the Normal Range and in the Normal Range for Calcium, Cholesterol, Chloride, Potassium, Sodium, Triglycerides, and Urea/Blood Urea Nitrogen (BUN) at Weeks 0, 6, 16, 28, 40, and 52/EW
participantsLamotrigine
Calcium, High, Week 0; n=921
Calcium, Normal, Week 0; n=9291
Calcium, Low, Week 0; n=920
Calcium, High, Week 6; n=844
Calcium, Normal, Week 6; n=8480
Calcium, Low, Week 6; n=840
Calcium, High, Week 16; n=782
Calcium, Normal, Week 16; n=7875
Calcium, Low, Week 16; n=781
Calcium, High, Week 28; n=771
Calcium, Normal, Week 28; n=7776
Calcium, Low, Week 28; n=770
Calcium, High, Week 40; n=701
Calcium, Normal, Week 40; n=7069
Calcium, Low, Week 40; n=700
Calcium, High, Week 52/EW; n=860
Calcium, Normal, Week 52/EW; n=8685
Calcium, Low, Week 52/EW; n=861
Cholesterol, High, Week 0; n=9221
Cholesterol, Normal, Week 0; n=9266
Cholesterol, Low, Week 0; n=925
Cholesterol, High, Week 6; n=8420
Cholesterol, Normal, Week 6; n=8457
Cholesterol, Low, Week 6; n=847
Cholesterol, High, Week 16; n=7816
Cholesterol, Normal, Week 16; n=7858
Cholesterol, Low, Week 16; n=784
Cholesterol, High, Week 28; n=7713
Cholesterol, Normal, Week 28; n=7761
Cholesterol, Low, Week 28; n=773
Cholesterol, High, Week 40; n=7020
Cholesterol, Normal, Week 40; n=7045
Cholesterol, Low, Week 40; n=705
Cholesterol, High, Week 52/EW; n=8618
Cholesterol, Normal, Week 52/EW; n=8664
Cholesterol, Low, Week 52/EW; n=864
Chloride, High, Week 0; n=922
Chloride, Normal Week 0; n=9290
Chloride, Low, Week 0; n=920
Chloride, High, Week 6; n=840
Chloride, Normal, Week 6; n=8484
Chloride, Low, Week 6; n=840
Chloride, High, Week 16; n=780
Chloride, Normal, Week 16; n=7877
Chloride, Low, Week 16; n=781
Chloride, High, Week 28; n=770
Chloride, Normal, Week 28; n=7776
Chloride, Low, Week 28; n=771
Chloride, High, Week 40; n=702
Chloride, Normal, Week 40; n=7066
Chloride, Low, Week 40; n=702
Chloride, High, Week 52/EW; n=863
Chloride, Normal, Week 52/EW; n=8679
Chloride, Low, Week 52/EW; n=864
Potassium, High, Week 0; n=920
Potassium, Normal, Week 0; n=9292
Potassium, Low, Week 0; n=920
Potassium, High, Week 6; n=841
Potassium, Normal, Week 6; n=8483
Potassium, Low, Week 6; n=840
Potassium, High, Week 16; n=782
Potassium, Normal, Week 16; n=7876
Potassium, Low, Week 16; n=780
Potassium, High, Week 28; n=770
Potassium, Normal, Week 28; n=7776
Potassium, Low, Week 28; n=771
Potassium, High, Week 40; n=702
Potassium, Normal, Week 40; n=7068
Potassium, Low, Week 40; n=700
Potassium, High, Week 52/EW; n=860
Potassium, Normal, Week 52/EW; n=8686
Potassium, Low, Week 52/EW; n=860
Sodium, High, Week 0; n=921
Sodium, Normal, Week 0; n=9290
Sodium, Low, Week 0; n=921
Sodium, High, Week 6; n=840
Sodium, Normal, Week 6; n=8483
Sodium, Low, Week 6; n=841
Sodium, High, Week 16; n=780
Sodium, Normal, Week 16; n=7877
Sodium, Low, Week 16; n=781
Sodium, High, Week 28; n=770
Sodium, Normal, Week 28; n=7776
Sodium, Low, Week 28; n=771
Sodium, High, Week 40; n=700
Sodium, Normal, Week 40; n=7069
Sodium, Low, Week 40; n=701
Sodium, High, Week 52/EW; n=861
Sodium, Normal, Week 52/EW; n=8683
Sodium, Low, Week 52/EW; n=862
Triglycerides, High, Week 0; n=9223
Triglycerides, Normal, Week 0; n=9255
Triglycerides, Low, Week 0; n=9214
Triglycerides, High, Week 6; n=8420
Triglycerides, Normal, Week 6; n=8450
Triglycerides, Low, Week 6; n=8414
Triglycerides, High, Week 16; n=7820
Triglycerides, Normal, Week 16; n=7850
Triglycerides, Low, Week 16; n=788
Triglycerides, High, Week 28; n=7723
Triglycerides, Normal, Week 28; n=7742
Triglycerides, Low, Week 28; n=7712
Triglycerides, High, Week 40; n=7018
Triglycerides, Normal, Week 40; n=7040
Triglycerides, Low, Week 40; n=7012
Triglycerides, High, Week 52/EW; n=8621
Triglycerides, Normal, Week 52/EW; n=8653
Triglycerides, Low, Week 52/EW; n=8612
Urea/BUN, High, Week 0; n=924
Urea/BUN, Normal, Week 0; n=9277
Urea/BUN, Low, Week 0; n=9211
Urea/BUN, High, Week 6; n=841
Urea/BUN, Normal, Week 6; n=8474
Urea/BUN, Low, Week 6; n=849
Urea/BUN, High, Week 16; n=785
Urea/BUN, Normal, Week 16; n=7868
Urea/BUN, Low, Week 16; n=785
Urea/BUN, High, Week 28; n=772
Urea/BUN, Normal, Week 28; n=7773
Urea/BUN, Low, Week 28; n=772
Urea/BUN, High, Week 40; n=705
Urea/BUN, Normal, Week 40; n=7056
Urea/BUN, Low, Week 40; n=709
Urea/BUN, High, Week 52/EW; n=865
Urea/BUN, Normal, Week 52/EW; n=8674
Urea/BUN, Low, Week 52/EW; n=867
PrimaryNumber of Participants With Clinical Laboratory Test Values Out of the Normal Range and in the Normal Range for Platelet Count and White Blood Cell Count at Weeks 0, 6, 16, 28, 40, and 52/EW

Participants in the study were evaluated for the following clinical laboratory parameters of hematology at the indicated time points: platelet count and white blood cell count. Participants were categorized as "High" for laboratory values above normal (reference) and as "Low" for laboratory values below normal ranges used by the central laboratory. Normal ranges: platelet count, 140-379 GI (gibi; 10\^9) per liter (GI/L); white blood cell count, 3.5-9.7 GI/L.

Time frame:
Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
Reported as:
Number · participants
Number of Participants With Clinical Laboratory Test Values Out of the Normal Range and in the Normal Range for Platelet Count and White Blood Cell Count at Weeks 0, 6, 16, 28, 40, and 52/EW
participantsLamotrigine
Platelet count, High, Week 0; n=923
Platelet count, Normal, Week 0; n=9289
Platelet count, Low, Week 0; n=920
Platelet count, High, Week 6; n=842
Platelet count, Normal, Week 6; n=8481
Platelet count, Low, Week 6; n=841
Platelet count, High, Week 16; n=782
Platelet count, Normal, Week 16; n=7875
Platelet count, Low, Week 16; n=781
Platelet count, High, Week 28; n=772
Platelet count, Normal, Week 28; n=7775
Platelet count, Low, Week 28; n=770
Platelet count, High, Week 40; n=680
Platelet count, Normal, Week 40; n=6868
Platelet count, Low, Week 40; n=680
Platelet count, High, Week 52/EW; n=863
Platelet count, Normal, Week 52/EW; n=8682
Platelet count, Low, Week 52/EW; n=861
White blood cell count, High, Week 0; n=927
White blood cell count, Normal, Week 0; n=9283
White blood cell count, Low, Week 0; n=922
White blood cell count, High, Week 6; n=841
White blood cell count, Normal, Week 6; n=8481
White blood cell count, Low, Week 6; n=842
White blood cell count, High, Week 16; n=781
White blood cell count, Normal, Week 16; n=7875
White blood cell count, Low, Week 16; n=782
White blood cell count, High, Week 28; n=772
White blood cell count, Normal, Week 28; n=7770
White blood cell count, Low, Week 28; n=775
White blood cell count, High, Week 40; n=693
White blood cell count, Normal, Week 40; n=6961
White blood cell count, Low, Week 40; n=695
White blood cell count, High, Week 52/EW; n=863
White blood cell count, Normal, Week 52/EW; n=8680
White blood cell count, Low, Week 52/EW; n=863
PrimaryNumber of Participants With Clinical Laboratory Test Values Out of the Normal Range and in the Normal Range for Total Protein, Hemoglobin, and Hematocrit at Weeks 0, 6, 16, 28, 40, and 52/EW

Participants in the study were evaluated for total protein, hemoglobin, and hematocrit at the indicated time points. Participants were categorized as "High" for laboratory values above normal (reference) and as "Low" for laboratory values below normal ranges used by the central laboratory. Normal ranges: total protein, 65-82 grams per liter (G/L); hemoglobin, Male: 136-183 G/L, Female: 112-152 G/L; hematocrit (proportion of 1), Male: 0.404-0.519, Female: 0.343-0.452.

Time frame:
Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
Reported as:
Number · participants
Number of Participants With Clinical Laboratory Test Values Out of the Normal Range and in the Normal Range for Total Protein, Hemoglobin, and Hematocrit at Weeks 0, 6, 16, 28, 40, and 52/EW
participantsLamotrigine
Total protein, High, Week 0; n=921
Total protein, Normal, Week 0; n=9285
Total protein, Low, Week 0; n=926
Total protein, High, Week 6; n=840
Total protein, Normal, Week 6; n=8477
Total protein, Low, Week 6; n=847
Total protein, High, Week 16; n=780
Total protein, Normal, Week 16; n=7874
Total protein, Low, Week 16; n=784
Total protein, High, Week 28; n=770
Total protein, Normal, Week 28; n=7769
Total protein, Low, Week 28; n=778
Total protein, High, Week 40; n=701
Total protein, Normal, Week 40; n=7064
Total protein, Low, Week 40; n=705
Total protein, High, Week 52/EW; n=860
Total protein, Normal, Week 52/EW; n=8672
Total protein, Low, Week 52/EW; n=8614
Hemoglobin, High, Week 0; n=924
Hemoglobin, Normal, Week 0; n=9280
Hemoglobin, Low, Week 0; n=928
Hemoglobin, High, Week 6; n=842
Hemoglobin, Normal, Week 6; n=8475
Hemoglobin, Low, Week 6; n=847
Hemoglobin, High, Week 16; n=783
Hemoglobin, Normal, Week 16; n=7868
Hemoglobin, Low, Week 16; n=787
Hemoglobin, High, Week 28; n=771
Hemoglobin, Normal, Week 28; n=7769
Hemoglobin, Low, Week 28; n=777
Hemoglobin, High, Week 40; n=691
Hemoglobin, Normal, Week 40; n=6962
Hemoglobin, Low, Week 40; n=696
Hemoglobin, High, Week 52/EW; n=864
Hemoglobin, Normal, Week 52/EW; n=8671
Hemoglobin, Low, Week 52/EW; n=8611
Hematocrit, High, Week 0; n=924
Hematocrit, Normal, Week 0; n=9283
Hematocrit, Low, Week 0; n=925
Hematocrit, High, Week 6; n=843
Hematocrit, Normal, Week 6; n=8475
Hematocrit, Low, Week 6; n=846
Hematocrit, High, Week 16; n=782
Hematocrit, Normal, Week 16; n=7873
Hematocrit, Low, Week 16; n=783
Hematocrit, High, Week 28; n=773
Hematocrit, Normal, Week 28; n=7769
Hematocrit, Low, Week 28; n=775
Hematocrit, High, Week 40; n=694
Hematocrit, Normal, Week 40; n=6963
Hematocrit, Low, Week 40; n=692
Hematocrit, High, Week 52/EW; n=863
Hematocrit, Normal, Week 52/EW; n=8673
Hematocrit, Low, Week 52/EW; n=8610
PrimaryNumber of Participants With Clinical Laboratory Test Values Out of the Normal Range and in the Normal Range for Red Blood Cell Count at Weeks 0, 6, 16, 28, 40, and 52/EW

Red blood cell count was measured in participants at the indicated time points. Participants were categorized as "High" for laboratory values above normal (reference) and as "Low" for laboratory values below normal ranges used by the central laboratory. Normal ranges: red blood cell count, Male: 4.38-5.77 TI (tebi; 10\^12)/L, Female: 3.76-5.16 TI/L.

Time frame:
Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
Reported as:
Number · participants
Number of Participants With Clinical Laboratory Test Values Out of the Normal Range and in the Normal Range for Red Blood Cell Count at Weeks 0, 6, 16, 28, 40, and 52/EW
participantsLamotrigine
Red blood cell count, High, Week 0; n=922
Red blood cell count, Normal, Week 0; n=9288
Red blood cell count, Low, Week 0; n=922
Red blood cell count, High, Week 6; n=841
Red blood cell count, Normal, Week 6; n=8478
Red blood cell count, Low, Week 6; n=845
Red blood cell count, High, Week 16; n=781
Red blood cell count, Normal, Week 16; n=7873
Red blood cell count, Low, Week 16; n=784
Red blood cell count, High, Week 28; n=771
Red blood cell count, Normal, Week 28; n=7770
Red blood cell count, Low, Week 28; n=776
Red blood cell count, High, Week 40; n=691
Red blood cell count, Normal, Week 40; n=6964
Red blood cell count, Low, Week 40; n=694
Red blood cell count, High, Week 52/EW; n=863
Red blood cell count, Normal, Week 52/EW; n=8672
Red blood cell count, Low, Week 52/EW; n=8611
PrimaryNumber of Participants in the Indicated Category for Urine Glucose, Urine Protein, and Urine Urobilinogen at Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW

Urine glucose, urine protein, and urine urobilinogen were measured in participants at the indicated time points. In this dipstick (qualitative) test, the level of glucose, protein, and urobilinogen in urine samples was recorded as negative (NEG \[-\]), trace (TRA \[+/-\]), 1+, 2+, 3+, 4+, and 5+ (the plus sign increases with a higher level of glucose, protein, or urobilinogen in the urine: 1+=slightly positive, 2+=positive, 3+=high positive, 4+=very high positive, 5+=more positive than 4+).

Time frame:
Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
Reported as:
Number · participants
Number of Participants in the Indicated Category for Urine Glucose, Urine Protein, and Urine Urobilinogen at Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
participantsLamotrigine
Urine Glucose, Week 0, NEG [-]; n=9288
Urine Glucose, Week 0, TRA [+/-]; n=921
Urine Glucose, Week 0, 1+; n=921
Urine Glucose, Week 0, 2+; n=921
Urine Glucose, Week 0, 3+; n=920
Urine Glucose, Week 0, 4+; n=921
Urine Glucose, Week 0, 5+; n=920
Urine Glucose, Week 6, NEG [-]; n=8481
Urine Glucose, Week 6, TRA [+/-]; n=840
Urine Glucose, Week 6, 1+; n=841
Urine Glucose, Week 6, 2+; n=841
Urine Glucose, Week 6, 3+; n=841
Urine Glucose, Week 6, 4+; n=840
Urine Glucose, Week 6, 5+; n=840
Urine Glucose, Week 16, NEG [-]; n=7877
Urine Glucose, Week 16, TRA [+/-]; n=780
Urine Glucose, Week 16, 1+; n=781
Urine Glucose, Week 16, 2+; n=780
Urine Glucose, Week 16, 3+; n=780
Urine Glucose, Week 16, 4+; n=780
Urine Glucose, Week 16, 5+; n=780
Urine Glucose, Week 28, NEG [-]; n=7776
Urine Glucose, Week 28, TRA [+/-]; n=771
Urine Glucose, Week 28, 1+; n=770
Urine Glucose, Week 28, 2+; n=770
Urine Glucose, Week 28, 3+; n=770
Urine Glucose, Week 28, 4+; n=770
Urine Glucose, Week 28, 5+; n=770
Urine Glucose, Week 40, NEG [-]; n=7068
Urine Glucose, Week 40, TRA [+/-]; n=702
Urine Glucose, Week 40, 1+; n=700
Urine Glucose, Week 40, 2+; n=700
Urine Glucose, Week 40, 3+; n=700
Urine Glucose, Week 40, 4+; n=700
Urine Glucose, Week 40, 5+; n=700
Urine Glucose, Week 52/EW, NEG [-]; n=8685
Urine Glucose, Week 52/EW, TRA [+/-]; n=860
Urine Glucose, Week 52/EW, 1+; n=861
Urine Glucose, Week 52/EW, 2+; n=860
Urine Glucose, Week 52/EW, 3+; n=860
Urine Glucose, Week 52/EW, 4+; n=860
Urine Glucose, Week 52/EW, 5+; n=860
Urine Protein, Week 0, NEG [-]; n=9287
Urine Protein, Week 0, TRA [+/-]; n=923
Urine Protein, Week 0, 1+; n=921
Urine Protein, Week 0, 2+; n=921
Urine Protein, Week 0, 3+; n=920
Urine Protein, Week 0, 4+; n=920
Urine Protein, Week 0, 5+; n=920
Urine Protein, Week 6, NEG [-]; n=8481
Urine Protein, Week 6, TRA [+/-]; n=841
Urine Protein, Week 6, 1+; n=842
Urine Protein, Week 6, 2+; n=840
Urine Protein, Week 6, 3+; n=840
Urine Protein, Week 6, 4+; n=840
Urine Protein, Week 6, 5+; n=840
Urine Protein, Week 16, NEG [-]; n=7876
Urine Protein, Week 16, TRA [+/-]; n=780
Urine Protein, Week 16, 1+; n=781
Urine Protein, Week 16, 2+; n=781
Urine Protein, Week 16, 3+; n=780
Urine Protein, Week 16, 4+; n=780
Urine Protein, Week 16, 5+; n=780
Urine Protein, Week 28, NEG [-]; n=7775
Urine Protein, Week 28, TRA [+/-]; n=770
Urine Protein, Week 28, 1+; n=772
Urine Protein, Week 28, 2+; n=770
Urine Protein, Week 28, 3+; n=770
Urine Protein, Week 28, 4+; n=770
Urine Protein, Week 28, 5+; n=770
Urine Protein, Week 40, NEG [-]; n=7069
Urine Protein, Week 40, TRA [+/-]; n=700
Urine Protein, Week 40, 1+; n=700
Urine Protein, Week 40, 2+; n=701
Urine Protein, Week 40, 3+; n=700
Urine Protein, Week 40, 4+; n=700
Urine Protein, Week 40, 5+; n=700
Urine Protein, Week 52/EW, NEG [-]; n=8681
Urine Protein, Week 52/EW, TRA [+/-]; n=861
Urine Protein, Week 52/EW, 1+; n=863
Urine Protein, Week 52/EW, 2+; n=861
Urine Protein, Week 52/EW, 3+; n=860
Urine Protein, Week 52/EW, 4+; n=860
Urine Protein, Week 52/EW, 5+; n=860
Urine Urobilinogen, Week 0, NEG [-]; n=920
Urine Urobilinogen, Week 0, TRA [+/-]; n=9288
Urine Urobilinogen, Week 0, 1+; n=924
Urine Urobilinogen, Week 0, 2+; n=920
Urine Urobilinogen, Week 0, 3+; n=920
Urine Urobilinogen, Week 0, 4+; n=920
Urine Urobilinogen, Week 0, 5+; n=920
Urine Urobilinogen, Week 6, NEG [-]; n=840
Urine Urobilinogen, Week 6, TRA [+/-]; n=8481
Urine Urobilinogen, Week 6, 1+; n=842
Urine Urobilinogen, Week 6, 2+; n=841
Urine Urobilinogen, Week 6, 3+; n=840
Urine Urobilinogen, Week 6, 4+; n=840
Urine Urobilinogen, Week 6, 5+; n=840
Urine Urobilinogen, Week 16, NEG [-]; n=780
Urine Urobilinogen, Week 16, TRA [+/-]; n=7876
Urine Urobilinogen, Week 16, 1+; n=782
Urine Urobilinogen, Week 16, 2+; n=780
Urine Urobilinogen, Week 16, 3+; n=780
Urine Urobilinogen, Week 16, 4+; n=780
Urine Urobilinogen, Week 16, 5+; n=780
Urine Urobilinogen, Week 28, NEG [-]; n=770
Urine Urobilinogen, Week 28, TRA [+/-]; n=7777
Urine Urobilinogen, Week 28, 1+; n=770
Urine Urobilinogen, Week 28, 2+; n=770
Urine Urobilinogen, Week 28, 3+; n=770
Urine Urobilinogen, Week 28, 4+; n=770
Urine Urobilinogen, Week 28, 5+; n=770
Urine Urobilinogen, Week 40, NEG [-]; n=700
Urine Urobilinogen, Week 40, TRA [+/-]; n=7068
Urine Urobilinogen, Week 40, 1+; n=702
Urine Urobilinogen, Week 40, 2+; n=700
Urine Urobilinogen, Week 40, 3+; n=700
Urine Urobilinogen, Week 40, 4+; n=700
Urine Urobilinogen, Week 40, 5+; n=700
Urine Urobilinogen, Week 52/EW, NEG [-]; n=860
Urine Urobilinogen, Week 52/EW, TRA [+/-]; n=8682
Urine Urobilinogen, Week 52/EW, 1+; n=864
Urine Urobilinogen, Week 52/EW, 2+; n=860
Urine Urobilinogen, Week 52/EW, 3+; n=860
Urine Urobilinogen, Week 52/EW, 4+; n=860
Urine Urobilinogen, Week 52/EW, 5+; n=860
PrimaryMean Systolic Blood Pressure and Diastolic Blood Pressure of Participants at Baseline (Week 0) and Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW

Systolic and diastolic blood pressure was measured in participants at the indicated time points.

Time frame:
Baseline (Week 0) and Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
Reported as:
Mean · Millimeters of mercury
Mean Systolic Blood Pressure and Diastolic Blood Pressure of Participants at Baseline (Week 0) and Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
Millimeters of mercuryLamotrigine
Systolic blood pressure, Week 0; n=92119.9 ± 15.40
Systolic blood pressure, Week 2; n=87121.7 ± 16.11
Systolic blood pressure, Week 4; n=85118.9 ± 15.77
Systolic blood pressure, Week 5; n=85119.0 ± 16.26
Systolic blood pressure, Week 6; n=84120.4 ± 16.09
Systolic blood pressure, Week 8; n=81118.6 ± 16.28
Systolic blood pressure, Week 12; n=79120.1 ± 15.71
Systolic blood pressure, Week 16; n=78119.1 ± 16.76
Systolic blood pressure, Week 20; n=77117.8 ± 15.04
Systolic blood pressure, Week 24; n=77118.5 ± 15.30
Systolic blood pressure, Week 28; n=77117.3 ± 18.84
Systolic blood pressure, Week 32; n=76121.8 ± 17.04
Systolic blood pressure, Week 36; n=73121.3 ± 15.80
Systolic blood pressure, Week 40; n=70118.2 ± 15.21
Systolic blood pressure, Week 44; n=69118.7 ± 14.88
Systolic blood pressure, Week 48; n=69121.2 ± 16.37
Systolic blood pressure, Week 52/EW; n=87118.2 ± 14.20
Diastolic blood pressure, Week 0; n=9274.2 ± 11.41
Diastolic blood pressure, Week 2; n=8774.9 ± 11.62
Diastolic blood pressure, Week 4; n=8574.2 ± 12.08
Diastolic blood pressure, Week 5; n=8573.8 ± 12.34
Diastolic blood pressure, Week 6; n=8473.7 ± 11.16
Diastolic blood pressure, Week 8; n=8172.6 ± 12.72
Diastolic blood pressure, Week 12; n=7973.2 ± 12.08
Diastolic blood pressure, Week 16; n=7873.0 ± 12.29
Diastolic blood pressure, Week 20; n=7773.6 ± 11.59
Diastolic blood pressure, Week 24; n=7774.2 ± 11.72
Diastolic blood pressure, Week 28; n=7771.1 ± 12.24
Diastolic blood pressure, Week 32; n=7674.0 ± 11.93
Diastolic blood pressure, Week 36; n=7372.4 ± 10.98
Diastolic blood pressure, Week 40; n=7072.3 ± 12.04
Diastolic blood pressure, Week 44; n=6973.0 ± 12.22
Diastolic blood pressure, Week 48; n=6972.7 ± 11.91
Diastolic blood pressure, Week 52/EW; n=8773.2 ± 11.69
PrimaryMean Heart Rate of Participants at Week 0 (Baseline) and Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW

Heart rate was measured in participants at the indicated time points.

Time frame:
Baseline (Week 0) and Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
Reported as:
Mean · beat per minute
Mean Heart Rate of Participants at Week 0 (Baseline) and Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
beat per minuteLamotrigine
Week 0; n=9276.3 ± 12.48
Week 2; n=8778.0 ± 12.77
Week 4; n=8577.4 ± 11.96
Week 5; n=8578.5 ± 12.54
Week 6; n=8477.0 ± 11.97
Week 8; n=8176.8 ± 11.34
Week 12; n=7979.0 ± 13.47
Week 16; n=7876.5 ± 11.81
Week 20; n=7777.4 ± 11.09
Week 24; n=7774.9 ± 12.50
Week 28; n=7775.9 ± 10.28
Week 32; n=7677.2 ± 12.23
Week 36; n=7376.8 ± 11.46
Week 40; n=7075.8 ± 10.63
Week 44; n=6977.3 ± 11.10
Week 48; n=6978.2 ± 11.63
Week 52/EW; n=8774.8 ± 11.75
PrimaryMean Weight of Participants at Baseline (Week 0) and Weeks 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW

The weight of participants was recorded at the indicated time points.

Time frame:
Baseline (Week 0) and Weeks 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
Reported as:
Mean · kilograms
Mean Weight of Participants at Baseline (Week 0) and Weeks 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
kilogramsLamotrigine
Week 0; n=9260.86 ± 12.532
Week 6; n=8461.62 ± 12.405
Week 8; n=8161.29 ± 12.420
Week 12; n=7961.26 ± 12.685
Week 16; n=7861.38 ± 12.753
Week 20; n=7761.19 ± 12.929
Week 24; n=7761.29 ± 12.712
Week 28; n=7760.99 ± 12.688
Week 32; n=7661.05 ± 12.840
Week 36; n=7361.06 ± 13.097
Week 40; n=7060.67 ± 13.214
Week 44; n=6960.72 ± 13.214
Week 48; n=6960.43 ± 13.056
Week 52/EW; n=8760.09 ± 12.765
PrimaryMean Body Mass Index (BMI) of All Participants at Week 0 (Baseline) and Weeks 6, 8, 12, 16, 20, 24, 28, 32,36, 40, 44, 48, and 52/EW

The BMI for participants was calculated at the indicated time points as body weight in kilograms divided by height in meters squared.

Time frame:
Baseline (Week 0) and Weeks 0, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
Reported as:
Mean · Kilograms per meters squared
Mean Body Mass Index (BMI) of All Participants at Week 0 (Baseline) and Weeks 6, 8, 12, 16, 20, 24, 28, 32,36, 40, 44, 48, and 52/EW
Kilograms per meters squaredLamotrigine
Week 0; n=9222.8 ± 3.934
Week 6; n=8423.01 ± 3.878
Week 8; n=8122.89 ± 3.863
Week 12; n=7922.93 ± 3.975
Week 16; n=7822.96 ± 3.965
Week 20; n=7722.86 ± 3.941
Week 24; n=7722.91 ± 3.916
Week 28; n=7722.80 ± 3.970
Week 32; n=7622.81 ± 4.016
Week 36; n=7322.71 ± 4.041
Week 40; n=7022.48 ± 3.820
Week 44; n=6922.51 ± 3.785
Week 48; n=6922.40 ± 3.750
Week 52/EW; n=8722.42 ± 3.818
PrimaryNumber of Participants With the Indicated Electrocardiogram (ECG) Findings at Weeks 0, 6, 28, and 52/EW

ECGs were recorded in participants at the indicated time points. ECG findings, as determined by the physicians, were reported as normal, abnormal but not clinically significant (NCS), abnormal but clinically significant (CS), and no result. Specific definitions of ECG categorizations were not provided; physicians were expected to apply reasonable standards of clinical judgment.

Time frame:
Weeks 0, 6, 28, and 52/EW
Reported as:
Number · participants
Number of Participants With the Indicated Electrocardiogram (ECG) Findings at Weeks 0, 6, 28, and 52/EW
participantsLamotrigine
Week 0, Normal; n=9273
Week 0, Abnormal-NCS; n=9219
Week 0, Abnormal-CS; n=920
Week 0, No result; n=920
Week 6, Normal; n=8469
Week 6, Abnormal-NCS; n=8415
Week 6, Abnormal-CS; n=840
Week 6, No result; n=840
Week 28, Normal; n=7762
Week 28, Abnormal-NCS; n=7715
Week 28, Abnormal-CS; n=770
Week 28, No result; n=770
Week 52 (EW), Normal; n=8468
Week 52 (EW), Abnormal-NCS; n=8415
Week 52 (EW), Abnormal-CS; n=841
Week 52 (EW), No result; n=840
SecondaryClinical Global Impressions of Severity (CGI-S) Total Score at Weeks 0, 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW

The CGI-S is a standardized assessment tool that uses a 7-point scale to assess a participant's severity of illness. The total score ranges from 0 to 7: 0=not assessed, 1=normal, 2=borderline ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severly ill, 7=extremely ill. Higher scores reflect a higher severity of current illness states. The number of participants with an assessment varied depending on the number of assessments completed at each visit (indicated time points).

Time frame:
Weeks 0, 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
Reported as:
Mean · scores on a scale
Clinical Global Impressions of Severity (CGI-S) Total Score at Weeks 0, 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
scores on a scaleLamotrigine
Week 0, LOCF; n=922.9 ± 1.10
Week 0, OC; n=922.9 ± 1.10
Week 2, LOCF; n=912.6 ± 1.19
Week 2, OC; n=872.5 ± 1.13
Week 4, LOCF; n=922.5 ± 1.17
Week 4, OC; n=852.3 ± 0.98
Week 5, LOCF; n=922.4 ± 1.16
Week 5, OC; n=852.2 ± 0.95
Week 6, LOCF; n=922.3 ± 1.13
Week 6, OC; n=842.2 ± 0.89
Week 8, LOCF; n=922.4 ± 1.16
Week 8, OC; n=812.2 ± 0.93
Week 12, LOCF; n=922.2 ± 1.20
Week 12, OC; n=792.0 ± 0.91
Week 16, LOCF; n=922.3 ± 1.21
Week 16, OC; n=782.1 ± 0.94
Week 20, LOCF; n=922.4 ± 1.22
Week 20, OC; n=772.1 ± 0.96
Week 24, LOCF; n=922.4 ± 1.20
Week 24, OC; n=772.2 ± 0.95
Week 28, LOCF; n=922.3 ± 1.24
Week 28, OC; n=772.1 ± 0.99
Week 32, LOCF; n=922.4 ± 1.19
Week 32, OC; n=762.2 ± 0.93
Week 36, LOCF; n=922.3 ± 1.23
Week 36, OC; n=732.0 ± 0.95
Week 40, LOCF; n=922.4 ± 1.22
Week 40, OC; n=702.1 ± 0.95
Week 44, LOCF; n=922.4 ± 1.23
Week 44, OC; n=692.1 ± 0.93
Week 48, LOCF; n=922.3 ± 1.23
Week 48, OC; n=692.0 ± 0.91
Week 52/EW, LOCF; n=922.1 ± 1.24
Week 52/EW, OC; n=872.1 ± 1.25
SecondaryChange From Baseline in the Clinical Global Impressions of Severity (CGI-S) Total Score at Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW

The CGI-S is a standardized assessment tool that uses a 7-point scale to assess a participant's severity of illness. The total score ranges from 0 to 7: 0=not assessed, 1=normal, 2=borderline ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severly ill, 7=extremely ill. Higher scores reflect a higher severity of current illness states. Change from baseline was calculated as the values at Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 (or EW) minus the baseline value (Week 0).

Time frame:
Baseline (Week 0) and Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
Reported as:
Mean · scores on a scale
Change From Baseline in the Clinical Global Impressions of Severity (CGI-S) Total Score at Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
scores on a scaleLamotrigine
Week 2, LOCF; n=91-0.3 ± 0.93
Week 2, OC; n=87-0.3 ± 0.92
Week 4, LOCF; n=92-0.4 ± 1.01
Week 4, OC; n=85-0.5 ± 0.96
Week 5, LOCF; n=92-0.5 ± 1.07
Week 5, LOCF; n=85-0.6 ± 1.03
Week 6, LOCF; n=92-0.6 ± 1.07
Week 6, OC; n=84-0.7 ± 1.02
Week 8, LOCF; n=92-0.5 ± 1.16
Week 8, LOCF; n=81-0.6 ± 1.14
Week 12, LOCF; n=92-0.7 ± 1.23
Week 12, OC; n=79-0.8 ± 1.19
Week 16, LOCF; n=92-0.6 ± 1.21
Week 16, OC; n=78-0.7 ± 1.17
Week 20, LOCF; n=92-0.5 ± 1.17
Week 20, OC; n=77-0.6 ± 1.14
Week 24, LOCF; n=92-0.5 ± 1.09
Week 24, OC; n=77-0.6 ± 1.05
Week 28, LOCF; n=92-0.5 ± 1.23
Week 28, OC; n=77-0.7 ± 1.21
Week 32, LOCF; n=92-0.5 ± 1.14
Week 32, OC; n=76-0.6 ± 1.11
Week 36, LOCF; n=92-0.6 ± 1.18
Week 36, OC; n=73-0.7 ± 1.13
Week 40, LOCF; n=92-0.5 ± 1.24
Week 40, OC; n=70-0.6 ± 1.22
Week 44, LOCF; n=92-0.5 ± 1.16
Week 44, OC; n=69-0.6 ± 1.11
Week 48, LOCF; n=92-0.6 ± 1.19
Week 48, OC; n=69-0.7 ± 1.14
Week 52/EW, LOCF; n=92-0.8 ± 1.19
Week 52/EW, OC; n=87-0.8 ± 1.19
SecondaryHamilton Rating Scale for Depression (HAM-D) Scale Total Score at Weeks 6, 16, 28, 40, and 52/EW

The HAMD-17 is a 17-item questionnaire that detects change and measures illness severity. Individual items were rated on a scale of 0-4 and 0-2, with the total HAMD-17 score ranging from 0 (not ill) to 52 (severely ill).

Time frame:
Weeks 6, 16, 28, 40, and 52/EW
Reported as:
Mean · scores on a scale
Hamilton Rating Scale for Depression (HAM-D) Scale Total Score at Weeks 6, 16, 28, 40, and 52/EW
scores on a scaleLamotrigine
Week 6, LOCF; n=915.2 ± 6.68
Week 6, OC; n=844.3 ± 4.85
Week 16, LOCF; n=916.1 ± 7.28
Week 16, OC; n=785.2 ± 6.01
Week 28, LOCF; n=915.5 ± 6.76
Week 28, OC; n=774.5 ± 5.13
Week 40, LOCF; n=915.9 ± 7.21
Week 40, OC; n=704.7 ± 5.53
Week 52/EW, LOCF; n=915.5 ± 7.30
Week 52/EW, OC; n=875.4 ± 7.38
SecondaryChange From Baseline in the Hamilton Rating Scale for Depression (HAM-D) Scale Total Score at Weeks 6, 16, 28, 40, and 52/EW

The HAMD-17 is a 17-item questionnaire that detects change and measures illness severity. Individual items were rated on a scale of 0-4 and 0-2, with the total HAMD-17 score ranging from 0 (not ill) to 52 (severely ill). Change from baseline was calculated as the values at Week 6, 16, 28, 40, and 52 (or EW) minus the baseline value (Week 0).

Time frame:
Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
Reported as:
Mean · scores on a scale
Change From Baseline in the Hamilton Rating Scale for Depression (HAM-D) Scale Total Score at Weeks 6, 16, 28, 40, and 52/EW
scores on a scaleLamotrigine
Week 6, LOCF; n=91-4.5 ± 7.37
Week 6, OC; n=84-4.7 ± 7.19
Week 16, LOCF; n=91-3.7 ± 7.51
Week 16, OC; n=78-3.8 ± 7.51
Week 28, LOCF; n=91-4.3 ± 7.62
Week 28, OC; n=77-4.5 ± 7.66
Week 40, LOCF; n=91-3.9 ± 7.77
Week 40, OC; n=70-3.9 ± 7.69
Week 52/EW, LOCF; n=91-4.3 ± 7.17
Week 52/EW, OC; n=87-4.1 ± 6.96
SecondaryYoung Mania Rating Scale (YMRS) Total Score at Weeks 6, 16, 28, 40, and 52/EW

The YMRS is an 11-item, multiple-choice diagnostic questionnaire used to measure the severity of disease in participants. Individual items (1=elevated mood, 2=increased motor activity, 3=sexual interest, 4=sleep, 5=irritability, 6=speech, 7=language thought disorder, 8=content, 9=disruptive aggressive behaviour, 10=appearance, 11=insight) were rated on a scale of 0-4 and 0-8. For all items, 0 is the "best" rating and 4 or 8 is the "worst" rating. YMRS total score was computed as the sum of the scores for the 11 items on the scale. The possible total scores range from 0 (best) to 60 (worst).

Time frame:
Weeks 6, 16, 28, 40, and 52/EW
Reported as:
Mean · scores on a scale
Young Mania Rating Scale (YMRS) Total Score at Weeks 6, 16, 28, 40, and 52/EW
scores on a scaleLamotrigine
Week 6, LOCF; n=913.2 ± 6.20
Week 6, OC; n=842.6 ± 4.37
Week 16, LOCF; n=912.6 ± 5.83
Week 16, OC; n=781.7 ± 3.02
Week 28, LOCF; n=912.8 ± 6.96
Week 28, OC; n=772.0 ± 5.19
Week 40, LOCF; n=912.7 ± 6.24
Week 40, OC; n=701.7 ± 3.95
Week 52/EW, LOCF; n=911.9 ± 5.55
Week 52/EW, OC; n=872.0 ± 5.66
SecondaryChange From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Weeks 6, 16, 28, 40, and 52/EW

The YMRS is an 11-item, multiple-choice diagnostic questionnaire used to measure the severity of disease in participants. Individual items (1=elevated mood, 2=increased motor activity, 3=sexual interest, 4=sleep, 5=irritability, 6=speech, 7=language thought disorder, 8=content, 9=disruptive aggressive behaviour, 10=appearance, 11=insight) were rated on a scale of 0-4 and 0-8. YMRS total score (range of 0-60) was computed as sum of the scores for the 11 items on the scale. Change from baseline was calculated as the values at Week 6, 16, 28, 40, and 52 (or EW) minus the baseline value (Week 0).

Time frame:
Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
Reported as:
Mean · scores on a scale
Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Weeks 6, 16, 28, 40, and 52/EW
scores on a scaleLamotrigine
Week 6, LOCF; n=910.2 ± 6.64
Week 6, OC; n=84-0.3 ± 5.88
Week 16, LOCF; n=91-0.4 ± 7.20
Week 16, OC; n=78-1.3 ± 6.13
Week 28, LOCF; n=91-0.2 ± 6.89
Week 28, OC; n=77-1.1 ± 5.75
Week 40, LOCF; n=91-0.3 ± 7.56
Week 40, OC; n=70-1.1 ± 6.73
Week 52/EW, LOCF; n=91-1.1 ± 7.11
Week 52/EW, OC; n=87-1.1 ± 7.27
SecondaryMedian Serum Lamotrigine 200 mg Concentration Among Participants With Concomitant Use of Inducer and Without Inhibitor (at the Timing of Blood Sample Collection)

Pharmacokinetic (PK) samples were collected at Weeks 6, 16, 28, 40, 52/EW, and the plasma lamotrigine concentrations were measured. Participants were required to visit the study site without taking the investigational product on the morning of the PK blood sampling. Inhibitors are defined as drugs that inhibit lamotrigine glucuronidation (i.e., valproate). Inducers are defined as drugs that induce lamotrigine glucuronidation (e.g., carbamazepine). The median value presented is the median of all samples collected at Weeks 6, 16, 28, 40, and 52/EW.

Time frame:
from Week 6 to Week 52/EW
Reported as:
Median · Nanograms per milliliter
Median Serum Lamotrigine 200 mg Concentration Among Participants With Concomitant Use of Inducer and Without Inhibitor (at the Timing of Blood Sample Collection)
Nanograms per milliliterLamotrigine
Median Serum Lamotrigine 200 mg Concentration Among Participants With Concomitant Use of Inducer and Without Inhibitor (at the Timing of Blood Sample Collection)1605.70 (0.00 to 3238.6)
SecondaryMedian Serum Lamotrigine 100 mg and 200 mg Concentration Among Participants With Concomitant Use of Inhibitor (at the Timing of Blood Sample Collection)

PK samples were collected at Weeks 6, 16, 28, 40, 52/EW, and the plasma lamotrigine concentrations were measured. Participants were required to visit the study site without taking the investigational product on the morning of the PK blood sampling. Inhibitors are defined as drugs that inhibit lamotrigine glucuronidation (i.e., valproate). The median value presented is the median of all samples collected at Weeks 6, 16, 28, 40, and 52/EW.

Time frame:
from Week 6 to Week 52/EW
Reported as:
Median · Nanograms per milliliter
Median Serum Lamotrigine 100 mg and 200 mg Concentration Among Participants With Concomitant Use of Inhibitor (at the Timing of Blood Sample Collection)
Nanograms per milliliterLamotrigine
Lamotrigine 100 mg; n=55312.30 (3762.7 to 15107.0)
Lamotrigine 200 mg; n=46935.40 (3210.2 to 9300.9)
SecondaryMedian Serum Lamotrigine 25, 100, 125, 150, 200, 225, 300, and 400 mg Concentrations Among Participants Without Concomitant Use of Inhibitor and Inducer

PK samples were collected at Weeks 6, 16, 28, 40, 52/EW, and the plasma lamotrigine concentrations were measured. Participants were required to visit the study site without taking the investigational product on the morning of the PK blood sampling. Inhibitors are defined as drugs that inhibit lamotrigine glucuronidation (i.e., valproate). Inducers are defined as drugs that induce lamotrigine glucuronidation (e.g., carbamazepine). The median value presented is the median of all samples collected at Weeks 6, 16, 28, 40, and 52/EW.

Time frame:
from Week 6 to Week 52/EW
Reported as:
Median · Nanograms per milliliter
Median Serum Lamotrigine 25, 100, 125, 150, 200, 225, 300, and 400 mg Concentrations Among Participants Without Concomitant Use of Inhibitor and Inducer
Nanograms per milliliterLamotrigine
Lamotrigine 25 mg; n=2699.95 (527.8 to 872.1)
Lamotrigine 100 mg; n=122793.55 (1486.7 to 7440.8)
Lamotrigine 125 mg; n=13505.30 (3505.3 to 3505.3)
Lamotrigine 150 mg; n=15418.40 (5418.4 to 5418.4)
Lamotrigine 200 mg; n=784092.30 (131.0 to 11053.2)
Lamotrigine 225 mg; n=13594.25 (2879.3 to 4309.2)
Lamotrigine 300 mg; n=75127.10 (3349.4 to 12066.6)
Lamotrigine 400 mg; n=48600.40 (4722.2 to 10830.3)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lamotrigine—13/92 (14.1%)52/92 (56.5%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventLamotrigine
ManiaPsychiatric disorders4/92
DepressionPsychiatric disorders2/92
Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/92
DeliriumPsychiatric disorders1/92
Self injurious behaviourPsychiatric disorders1/92
Suicidal ideationPsychiatric disorders1/92
Sick sinus syndromeCardiac disorders1/92
PharyngitisInfections and infestations1/92
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/92
Ovarian hemorrhageReproductive system and breast disorders1/92
Most frequent other events
Most frequent other events
EventLamotrigine
NasopharyngitisInfections and infestations36/92
Abdominal pain upperGastrointestinal disorders14/92
StomatitisGastrointestinal disorders11/92
NauseaGastrointestinal disorders7/92
VomitingGastrointestinal disorders7/92
DiarrheaGastrointestinal disorders6/92
HeadacheNervous system disorders6/92
AnemiaBlood and lymphatic system disorders5/92
Back painMusculoskeletal and connective tissue disorders5/92

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Lamotrigine
Mean43.5 ± 12.11
Sex: Female, Male
Sex: Female, Male(Participants)Lamotrigine
Female52
Male40
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Lamotrigine
Asian - Japanese Heritage91
Asian - East Asian Heritage1
08

Study locations

52 sites
  • GSK Investigational Site
    Aichi, 470-1141, Japan
  • GSK Investigational Site
    Chiba, 260-8677, Japan
  • GSK Investigational Site
    Chiba, 272-8516, Japan
  • GSK Investigational Site
    Chiba, 289-2511, Japan
  • GSK Investigational Site
    Fukuoka, 800-0217, Japan
  • GSK Investigational Site
    Fukuoka, 807-8555, Japan
  • GSK Investigational Site
    Fukuoka, 810-0004, Japan
  • GSK Investigational Site
    Fukuoka, 812-8582, Japan
  • GSK Investigational Site
    Fukuoka, 814-0180, Japan
  • GSK Investigational Site
    Fukuoka, 815-0041, Japan
  • GSK Investigational Site
    Fukuoka, 830-0011, Japan
  • GSK Investigational Site
    Gunma, 375-0017, Japan
  • GSK Investigational Site
    Gunma, 377-0055, Japan
  • GSK Investigational Site
    Hiroshima, 734-8551, Japan
  • GSK Investigational Site
    Hiroshima, 737-0023, Japan
  • GSK Investigational Site
    Hokkaido, 002-8029, Japan
  • GSK Investigational Site
    Hokkaido, 060-0042, Japan
  • GSK Investigational Site
    Hokkaido, 060-8648, Japan
  • GSK Investigational Site
    Ibaraki, 311-3193, Japan
  • GSK Investigational Site
    Kanagawa, 216-8511, Japan
  • GSK Investigational Site
    Kanagawa, 221-0835, Japan
  • GSK Investigational Site
    Kanagawa, 224-8503, Japan
  • GSK Investigational Site
    Kanagawa, 225-0011, Japan
  • GSK Investigational Site
    Kanagawa, 231-0023, Japan
  • GSK Investigational Site
    Kanagawa, 238-0042, Japan
  • GSK Investigational Site
    Kumamoto, 861-8002, Japan
  • GSK Investigational Site
    Kyoto, 616-8421, Japan
  • GSK Investigational Site
    Mie, 510-8575, Japan
  • GSK Investigational Site
    Mie, 515-0044, Japan
  • GSK Investigational Site
    Nara, 634-8522, Japan
  • GSK Investigational Site
    Oita, 874-0011, Japan
  • GSK Investigational Site
    Oita, 879-5593, Japan
  • GSK Investigational Site
    Oita, 879-7501, Japan
  • GSK Investigational Site
    Okayama, 700-8558, Japan
  • GSK Investigational Site
    Osaka, 569-1041, Japan
  • GSK Investigational Site
    Osaka, 583-0884, Japan
  • GSK Investigational Site
    Osaka, 590-0018, Japan
  • GSK Investigational Site
    Saga, 842-0192, Japan
  • GSK Investigational Site
    Saitama, 332-0012, Japan
  • GSK Investigational Site
    Tokyo, 113-8603, Japan
  • GSK Investigational Site
    Tokyo, 151-0053, Japan
  • GSK Investigational Site
    Tokyo, 152-0012, Japan
  • GSK Investigational Site
    Tokyo, 154-0004, Japan
  • GSK Investigational Site
    Tokyo, 166-0003, Japan
  • GSK Investigational Site
    Tokyo, 170-0002, Japan
  • GSK Investigational Site
    Tokyo, 173-0037, Japan
  • GSK Investigational Site
    Tokyo, 180-0005, Japan
  • GSK Investigational Site
    Tokyo, 183-0042, Japan
  • GSK Investigational Site
    Tokyo, 187-8551, Japan
  • GSK Investigational Site
    Tokyo, 190-0023, Japan
  • GSK Investigational Site
    Tottori, 682-0023, Japan
  • GSK Investigational Site
    Yamagata, 999-2221, Japan
09

References and documents

Publications

  • Tsukasa Koyama, Teruhiko Higuchi, Shigeto Yamawaki, Shigenobu Kanba, Takeshi Terao and Atsuko Shinohara. Study SCA106052, a clinical evaluation of BW430C (lamotrigine) in bipolar I disorder - Long-term extension study -. Rinsho seishin igaku. 2011;40(7):981-995.

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2011, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2007
First posted
Nov 30, 2007
Start
May 2008
Primary completionActual
Oct 2010
CompletionActual
Oct 2010
Results first posted
Jul 27, 2011
Last update
Apr 4, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00566020
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 30, 2007
Start date
May 2008
Primary completion
Oct 2010
Completion
Oct 2010
Results posted
Jul 27, 2011
Last update
Apr 4, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamotrigine

Start the discussion